InvestorsObserver
×
News Home

Is Menlo Therapeutics Inc (MNLO) a Winner in the Biotechnology Industry?

Monday, August 31, 2020 03:16 PM | InvestorsObserver Analysts

Mentioned in this article

Is Menlo Therapeutics Inc (MNLO) a Winner in the Biotechnology Industry?

The 39 rating InvestorsObserver gives to Menlo Therapeutics Inc (MNLO) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 29 percent of stocks in the Biotechnology industry, MNLO’s 39 overall rating means the stock scores better than 39 percent of all stocks.

Overall Score - 39
MNLO has an Overall Score of 39. Find out what this means to you and get the rest of the rankings on MNLO!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 39 would rank higher than 39 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Menlo Therapeutics Inc Stock Today?

Menlo Therapeutics Inc (MNLO) stock has risen 4.73% while the S&P 500 is lower by -0.03% as of 3:12 PM on Monday, Aug 31. MNLO is up $0.07 from the previous closing price of $1.48 on volume of 1,790,999 shares. Over the past year the S&P 500 has gained 20.67% while MNLO is lower by -67.98%. MNLO lost -$3.75 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App